Discontinuation of statins among patients with type 2 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 28, Issue 3, 2012, Pages 241-245

  Lamberts, E J F ^a   Nijpels, G ^b   Welschen, L M C ^b   Hugtenburg, J G ^b   Dekker, J M ^b   Souverein, P C ^a   Bouvy, M L ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adherence; Cardiovascular risk management; Discontinuation; Oral anti diabetics; Statins; Type 2 diabetes

Indexed keywords

ANTIDEPRESSANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COUMARIN DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; METFORMIN; NEUROLEPTIC AGENT; NITRATE; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DIABETIC PATIENT; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL;

ADULT; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; MEDICATION ADHERENCE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 84858144609     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1293     Document Type: Article

References (30)

1. Grant RW, Meigs JB. Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction. Diabetes Care 2007; 30: 479-484.
2. Berlowitz DR, Ash AS, Hickey EC, Glickman M, Friedman R, Kader B. Hypertension management in patients with diabetes: the need for more aggressive therapy. Diabetes Care 2003; 26: 355-359.
3. Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006; 332: 1115-24.
4. Kamari Y, Bitzur R, Cohen H, Shaish A, Harats D. Should all diabetic patients be treated with a statin? Diabetes Care 2009; 32(Suppl 2): S378-83.
5. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 2007; 30(Suppl 1): S4-S41.
6. Greving JP, Denig P, de Zeeuw D, Bilo HJ, Haaijer-Ruskamp FM. Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 1998-2004: a longitudinal observational study. Cardiovasc Diabetol 2007; 6: 25. doi:10.1186/1475-2840-6-25.
7. Berthold HK, Gouni-Berthold I, Bohm M, Krone W, Bestehorn KP. Patterns and predictors of statin prescription in patients with type 2 diabetes. Cardiovasc Diabetol 2009; 8: 25. doi:10.1186/1475-2840-8-25.
8. Yong TY, Phillipov G, Phillips PJ. Management outcomes of patients with type 2 diabetes: targeting the 10-year absolute risk of coronary heart disease. Med J Aust 2007; 186: 622-624.
9. Chodick G, Shalev V, Gerber Y, Heymann AD, Silber H, Simah V, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008; 30: 2167-2179.
10. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009; 15: 728-740.
11. van Bruggen R, Gorter K, Stolk RP, Zuithoff P, Klungel OH, Rutten GE. Refill adherence and polypharmacy among patients with type 2 diabetes in general practice. Pharmacoepidemiol Drug Saf 2009; 18: 983-991.
12. Donnelly LA, Doney AS, Morris AD, Palmer CN, Donnan PT. Long-term adherence to statin treatment in diabetes. Diabet Med 2008; 25: 850-855.
13. Dominguez H, Schramm TK, Norgaard ML, Abildstrom SZ, Kober L, Jorgensen C, et al. Initiation and persistence to statin treatment in patients with diabetes receiving glucose-lowering medications 1997-2006. Open Cardiovasc Med J 2009; 3: 152-159.
14. Ruokoniemi P, Korhonen MJ, Helin-Salmivaara A, Lavikainen P, Jula A, Junnila SY, et al. Statin adherence and the risk of major coronary events in patients with diabetes: a nested case-control study. Br J Clin Pharmacol 2011; 71: 766-776.
15. CBS. Statistics Netherlands. [cited 14 December 2010].
16. WHO. Collaborating Centre for Drug Statistics Methodology [database on the Internet]. WHO Collaborating Centre for Drug Statistics Methodology.
17. Norwegian Institute of Public Health. 2011 [cited 20 June 2011]. Available from:.
18. Buurma H, Bouvy ML, De Smet PA, Floor-Schreudering A, Leufkens HG, Egberts AC. Prevalence and determinants of pharmacy shopping behaviour. J Clin Pharm Ther 2008; 33: 17-23.
19. Bouma M, Rutten GE, de Grauw WJ, Wiersma T, Goudswaard AN. Summary of the practice guideline 'Diabetes mellitus type 2' (second revision) from the Dutch College of General Practitioners. Ned Tijdschr Geneeskd 2006; 150: 2251-2256.
20. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
21. Segars LW, Lea AR. Assessing prescriptions for statins in ambulatory diabetic patients in the United States: a national, cross-sectional study. Clin Ther 2008; 30: 2159-2166.
22. Teeling M, Bennet K, Feely J. The influence of guidelines on the use of statins: analysis of prescribing trends 1998-2002. Br J Clin Pharmacol 2005; 59: 227-232.
23. Voorham J, Haaijer-Ruskamp F, van der Meer K, de Zeeuw D, Wolffenbuttel B, Hoogenberg K, et al. Quality of diabetes type 2 treatment (Kwaliteit van de behandeling van type 2 diabetes). Ned Tijdschr Geneeskd 2010; 154: A775.
24. Wan Q, Harris MF, Jayasinghe UW, Flack J, Georgiou A, Penn DL, et al. Quality of diabetes care and coronary heart disease absolute risk in patients with type 2 diabetes mellitus in Australian general practice. Qual Saf Health Care 2006; 15: 131-135.
25. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. Br J Gen Pract 2009; 59: 43-48.
26. Yang Y, Thumula V, Pace PF, Banahan BF, 3rd, Wilkin NE, Lobb WB. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study. Clin Ther 2009; 31: 2178-2188; discussion 50-51.
27. Elisabeth AB, Denig P, van Vliet T, Dekker JH. Reasons of general practitioners for not prescribing lipid-lowering medication to patients with diabetes: a qualitative study. BMC Fam Pract 2009; 10: 24. doi:10.1186/1471-2296-10-24.
28. Adriaanse MC, Snoek FJ, Dekker JM, van der Ploeg HM, Heine RJ. Screening for Type 2 diabetes: an exploration of subjects' perceptions regarding diagnosis and procedure. Diabet Med 2002; 19: 406-411.
29. Adriaanse MC, Snoek FJ. The psychological impact of screening for type 2 diabetes. Diabetes Metab Res Rev 2006; 22: 20-25.
30. Vink NM, Klungel OH, Stolk RP, Denig P. Comparison of various measures for assessing medication refill adherence using prescription data. Pharmacoepidemiol Drug Saf 2009; 18: 159-165.